Manisha H. Shah
Ohio State University
184 Papers
1.8K Citations
Manisha H. Shah is an academic researcher from Ohio State University. The author has contributed to research in topics: Medicine & Neuroendocrine tumors. The author has an hindex of 55, co-authored 173 publications. Previous affiliations of Manisha H. Shah include University of Cincinnati Academic Health Center & The Ohio State University Wexner Medical Center.
Chat about Author
Papers
Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.
Kate Newbold,Rossella Elisei,Matthew H. Taylor,Monika K. Krzyzanowska,Manisha H. Shah,Ana O. Hoff,Bruce G. Robinson,Corina E. Dutcus,James Song,Mouhammed Amir Habra +9 more
TL;DR: The prespecified analysis of LEN-treated pts based on prior VEGF-targeted therapy exposure found that LEN prolonged PFS vs placebo in both groups.
Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure
George D. Demetri,Christopher R. Garrett,Patrick Schöffski,Manisha H. Shah,Jaap Verweij,Serge Leyvraz,Herbert Hurwitz,Antonio López Pousa,Axel Le Cesne,David Goldstein,Luis Paz-Ares,Luis Paz-Ares,Jean-Yves Blay,Grant A. McArthur,Qiang Casey Xu,Xin Huang,Charles S. Harmon,V. Tassell,Darrel P. Cohen,Paolo G. Casali +19 more
TL;DR: The cross-over design provided evidence of sunitinib clinical benefit based on prolonged time to tumor progression during the double-blind phase of this trial, and as expected, following cross- over, there was no statistical difference in OS.
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.
Aurélien Marabelle,Philippe A. Cassier,Marwan Fakih,Steven Kao,Dorte Nielsen,Antoine Italiano,Tormod Kyrre Guren,M. G. J. van Dongen,Kristen Spencer,Giovanni M. Bariani,Paolo A. Ascierto,Armando Santoro,Manisha H. Shah,Jamil Asselah,Syma Iqbal,T. Takahashi,Sarina Anne Piha-Paul,Patrick A. Ott,Arkendu Chatterjee,Fan Jin,Kevin Norwood,Jean-Pierre Delord +21 more
TL;DR: Pembrolizumab monotherapy is a possible treatment option with a favourable benefit-risk ratio for patients with previously treated advanced anal squamous cell carcinoma who have no alternative satisfactory treatment options.
The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
TL;DR: The management of advanced well-differentiated GEP-NETS is reviewed with a particular emphasis on the role of targeted therapies, both effectively controlling symptoms of hormonal overproduction and contributing to slowing tumor progression.
Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma.
Thomas J. Giordano,Bryan R. Haugen,Steven I. Sherman,Manisha H. Shah,Elaine M. Caoili,Ronald J. Koenig +5 more
TL;DR: Pioglitazone may be therapeutic in patients with PPFP thyroid cancer, however, thyroid cancers that are progressive despite standard-of-care therapy appear to only rarely express PPFP.